Platelet activation in acute myocardial infarction and the rationale for combination therapy. Review uri icon

Overview

abstract

  • Current fibrinolytic regimens fail to fully restore coronary blood flow in slightly less than 50% of patients with acute myocardial infarction. Platelet activation and aggregation may be responsible for a large proportion of these therapeutic failures. Therefore, platelet inhibition may enhance thrombolysis. Experimental and early clinical evidence suggest that glycoprotein IIb/IIIa antagonists may enhance reperfusion when combined with reduced doses of thrombolytic agents. However, the clinical benefit of combination therapy will depend on the outcomes of a number large clinical trials that are currently being performed.

publication date

  • September 1, 2000

Research

keywords

  • Angina, Unstable
  • Myocardial Infarction
  • Platelet Activation
  • Platelet Aggregation
  • Thrombolytic Therapy

Identity

Scopus Document Identifier

  • 0034265996

Digital Object Identifier (DOI)

  • 10.1007/s11886-000-0050-1

PubMed ID

  • 10980904

Additional Document Info

volume

  • 2

issue

  • 5